THE SMART TRICK OF MCC950 SDS THAT NO ONE IS DISCUSSING

expression, which can be a key driver of NIH. Within an in vivo mouse model of NIH in vascular grafts, MCC950 drastically Improved re‐endothelialization and lowered NIH in comparison to PTX or SMS.] Despite the brief‐term Gains PTX and SMS have on NIH, a limitation of these anti‐proliferative agents is delayed re‐endothelialization.[] Even